Eton Pharmaceuticals, Inc. ETON
64.35 USD +7.89 (+13.97%)
At closeNov 9, 2026, 7:47 PM EST
64.79 +0.44 +0.68%
After hours · Nov 9, 7:47 PM ET
57.02 Day range 64.44
14.27 52-week range 66.37
- YTD
- +280.54%
- 1 year
- +280.77%
News
benzinga.com Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $68 to $80.- benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $70 to $80.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
zacks.com Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
marketbeat.com Eton Pharmaceuticals Q3 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and…
benzinga.com Eton Pharmaceuticals Q3 2026 Earnings Call Transcript Eton Pharmaceuticals (NASDAQ:ETON) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced
globenewswire.com Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
globenewswire.com Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including…
zacks.com ETON Gears Up to Report Q3 Earnings: What Can Investors Expect? Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
benzinga.com Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027 ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like…
globenewswire.com Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing…
benzinga.com Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
benzinga.com HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and maintains $70 price target.- benzinga.com Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027 Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually…
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Jim Cramer: 'You Could Make Some Money With This 5.6% Yield' Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on BillionToOne, and calls Eton Pharma a winner.
benzinga.com Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.- benzinga.com Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68 Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
benzinga.com Dow Falls Over 100 Points; US Consumer Sentiment Declines In August Dow falls 0.26% while Nasdaq drops 0.51%. Energy shares rise 1.3%, tech stocks fall 0.6%. US retail sales down 0.6%, consumer sentiment declines.
benzinga.com B. Riley Securities Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $70 B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $70.
benzinga.com Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected earnings. Other big gains include ETON, VALN, IMXI.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
benzinga.com Applied Industrial Technologies To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday Top analysts changed outlook on top names. Mizuho raised price target for AIT from $355 to $400. See how analysts view AIT, ETON, PLGO, BRZE, VERI, POWL, AMAT, and YETI.
benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $70 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $65 to $70.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.- benzinga.com Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
- benzinga.com Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of…
benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $65 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $57 to $65.- benzinga.com Eton Pharmaceuticals Licenses U.S. Rights To Rare Disease Product Candidate ASN-001 From Auson Pharmaceuticals For Treatment Of Proliferating Superficial Infantile Hemangiomas ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently treated off-label with topical timololComplementary product to HEMANGEOL® (propranolol hydrochloride)…
- benzinga.com Eton Pharmaceuticals Submits FDA Prior Approval Supplement For Its New Formulation Of KHINDIVI Oral Solution New formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALKINDI SPRINKLE (hydrocortisone) oral granules, the FDA-approved hydrocortisone granule formulation,…
- benzinga.com Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62 Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $40 to $62.
- benzinga.com Canaccord Genuity Initiates Coverage On Eton Pharmaceuticals with Buy Rating, Announces Price Target of $60 Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) with a Buy rating and announces Price Target of $60.
- benzinga.com Eton Pharma Enters Into Supply And Distribution Agreement For US Commercialization Rights To IMPAVIDO From Affiliate Of Knight Therapeutics IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially…
benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $57 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $52 to $57.- benzinga.com Full Transcript: Eton Pharmaceuticals Q1 2026 Earnings Call
benzinga.com Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of…
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Eton Pharma Announces First Patient Dosed In Pilot Clinical Study Assessing Efficacy Of ET-700 For Treatment Of Wilson Disease; Topline Study Results Expected In H2 2026 Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the…
benzinga.com The Insider Report: Markets Wade into Geopolitical Abyss - benzinga.com B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $31 B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $26 to $31.
- benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $52 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $37 to $52.
- benzinga.com Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35 Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $30 to $35.
- benzinga.com Eton Pharmaceuticals Q4 Adj. EPS $0.19 Beats $0.09 Estimate, Sales $21.281M Beat $20.579M Estimate Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.09 by 111.11 percent. This is a 1050 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 19, 2026
- benzinga.com Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $30 Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $29 to $30.
- benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $37 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $35 to $37.